IgA Nephropathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
IgA Nephropathy Market Outlook
Thelansis’s “IgA Nephropathy Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential IgA Nephropathy treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
IgA
Nephropathy Overview
IgA
nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis
worldwide. The fundamental issue of this condition lies in the abnormal
glycosylation of O-linked glycans (glycoproteins) within the hinge region of
IgA1 throughout the body. Consequently, there are increased galactose-deficient
IgA1 (GdIgA1) levels in the bloodstream, targeted by glycan-specific IgA and
IgG autoantibodies. IgA, an antibody integral to mucosal immunity, occurs in
two isotypes, namely IgA1 and IgA2. It can also exist as a dimeric structure
known as secretory IgA. Plasma cells mainly produce secretory IgA in a
polymeric form, consisting of multiple monomers linked by the J-chain, a 17-kDa
polypeptide. In IgAN, the kidneys sustain the primary damage. The disease follows
a gradual yet relentless clinical course, leading to end-stage renal disease
(ESRD) in approximately 30-40% of patients within 20-30 years. IgAN can
manifest in sporadic cases (90-95%) or familial cases (5-10%). Individuals with
familial IgAN may experience a more unfavorable prognosis than those with
sporadic forms since they are more likely to progress to renal failure.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment